484 results on '"Lehman T"'
Search Results
2. Snowmass 2021 Computational Frontier CompF4 Topical Group Report: Storage and Processing Resource Access
3. Arsenic mobilization in aquifer sediments in the southwest USA
4. The prospective juvenile systemic sclerosis inceptions cohort – http://www.juvenile-scleroderma.com
5. Software-Defined Network for End-to-end Networked Science at the Exascale
6. FABRIC: A National-Scale Programmable Experimental Network Infrastructure
7. SDN for End-to-End Networked Science at the Exascale (SENSE)
8. The future of distributed network research infrastructure
9. AB1701 IS THERE A DIFFERENCE IN THE NUMBER OF INVOLVED ORGAN SYSTEMS BETWEEN JUVENILE DIFFUSE AND LIMITED SUBTYPE SYSTEMIC SCLEROSIS PATIENTS?
10. POS0758 PRESENCE OF NAILFOLD CAPILLARY CHANGES CORRELATES WITH MORE SEVERE ORGAN INVOLVEMENT IN JUVENILE SYSTEMIC SCLERODERMA. RESULTS OF THE JUVENILE SCLERODERMA INCEPTION COHORT.
11. POS0770 DIFFERENCES IN CLINICAL PRESENTATION BETWEEN JUVENILE SYSTEMIC SCLEROSIS PATIENTS WITH DIFFUSE AND LIMITED SUBTYPE. RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT.
12. POS0139 DIFFUSE JUVENILE SYSTEMIC SCLEROSIS PATIENTS SHOW DISTINCT ORGAN INVOLVEMENT, ANTIBODY PATTERN AND HAVE SIGNIFICANTLY MORE SEVERE DISEASE IN THE LARGEST JSSC COHORT OF THE WORLD. RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT
13. POS0140 PATIENT AND PHYSICIAN REPORTED OUTCOMES OF JUVENILE SYSTEMIC SCLEROSIS PATIENTS SIGNIFICANTLY IMPROVE OVER 24 MONTHS OBSERVATION PERIOD IN THE JUVENILE SYSTEMIC SCLERODERMA INCEPTION COHORT
14. POS0141 APPLICATION OF CRISS SCORE, REVISED CRISS SCORE AND RCID SCORE IN PATIENTS WITH JUVENILE SYSTEMIC SCLEROSIS
15. POS1550 IMPACT OF ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, DEUCRAVACITINIB, ON PSORIASIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2 TRIAL
16. Detrital Zircon Link Between Headwaters and Terminus of the Upper Triassic Chinle-Dockum Paleoriver System
17. Application of CRISS score, revised CRISS score and RCID score in patients with Juvenile systemic sclerosis
18. Patient and physician reported outcomes of juvenile systemic sclerosis patients significantly improve over 24 months observation period in the juvenile systemic scleroderma inception cohort
19. Diffuse juvenile systemic sclerosis patients show distinct organ involvement, antibody pattern and have significantly more severe disease in the largest jSSc cohort of the world. Results from the juvenile scleroderma inception cohort
20. Is decreased body mass index-2 z score or less correlating with an organ involvement pattern? Results from the juvenile scleroderma inception cohort
21. Diffuse juvenile systemic sclerosis patients show distinct organ involvement and have more severe disease in the largest jSSc cohort of the world. Results from the the juvenile scleroderma inception cohort
22. Juvenile systemic sclerosis treatment practices in an international cohort and comparison to recent SHARE consensus guidelines
23. Clinical characteristics of juvenile onset systemic sclerosis patients from the juvenile scleroderma inception cohort compared to adult age juvenile-onset patients from EUSTAR. Are these differences suggesting risk for mortality?
24. POS0172 DIFFUSE JUVENILE SYSTEMIC SCLEROSIS PATIENTS SHOW DISTINCT ORGAN INVOLVEMENT AND HAVE MORE SEVERE DISEASE IN THE LARGEST jSSc COHORT OF THE WORLD. RESULTS FROM THE THE JUVENILE SCLERODERMA INCEPTION COHORT. www.juvenile-scleroderma.com
25. AB1236 CLINICAL CHARACTERISTICS OF JUVENILE ONSET SYSTEMIC SCLEROSIS PATIENTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT COMPARED TO ADULT AGE JUVENILE-ONSET PATIENTS FROM EUSTAR. ARE THESE DIFFERENCES SUGGESTING RISK FOR MORTALITY?
26. AB0891 Deucravacitinib Efficacy in Psoriatic Arthritis by Baseline DMARD Use: Exploratory Analysis From a Phase 2 Study
27. POS1039 DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS: ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND ITS COMPONENTS
28. POS1299 JUVENILE SYSTEMIC SCLEROSIS TREATMENT PRACTICES IN AN INTERNATIONAL COHORT AND COMPARISON TO RECENT SHARE CONSENSUS GUIDELINES.
29. POS1040 SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS – RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS
30. POS1048 SAFETY AND EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM A RANDOMISED PHASE 2 TRIAL
31. AB0883 Real-World Treatment Patterns In Patients With Psoriatic Arthritis
32. Systemic Lupus Erythematosus: Etiology, Pathogenesis, Clinical Manifestations, and Management
33. Making Real Data Persistent: Initial Experiences with SMRC
34. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis
35. Patients with juvenile systemic sclerosis have a distinct pattern of organ involvement. Results from thejuvenile systemic sclerosis inception cohort
36. Javelinoxylon, an Upper Cretaceous Dicotyledonous Tree from Big Bend National Park, Texas, with Presumed Malvalean Affinities
37. Differences sustained between diffuse and limited forms of juvenile systemic sclerosis in expanded international cohort. www.juvenile-scleroderma.com
38. Patients with Juvenile Systemic Sclerosis Have a Distinct Pattern of Organ Involvement: Results from the Juvenile Systemic Sclerosis Inception Cohort
39. Male Juvenile Systemic Sclerosis Patients Have More Severe Disease: Results from the International Juvenile Scleroderma Inception Cohort
40. Juvenile systemic sclerosis (jSSc) patients with overlap characteristics do not have mild disease.Results from thejSSc inception cohort
41. POS1304 JUVENILE SYSTEMIC SCLEROSIS (JSSC) PATIENTS WITH OVERLAP CHARACTERISTICS DO NOT HAVE MILD DISEASE. RESULTS FROM THE JSSC INCEPTION COHORT. WWW.JUVENILESCLERODERMA.COM
42. OP0227 EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MUSCULOSKELETAL MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
43. AB0560 EFFECT OF DEUCRAVACITINIB ON THE PSORIATIC ARTHRITIS IMPACT OF DISEASE (PsAID) QUESTIONNAIRES 12 AND 9: ANALYSIS OF A PHASE 2 STUDY OF ACTIVE PSORIATIC ARTHRITIS
44. POS0079 PATIENTS WITH JUVENILE SYSTEMIC SCLEROSIS HAVE A DISTINCT PATTERN OF ORGAN INVOLVEMENT.RESULTS FROM THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT. WWW.JUVENILE-SCLERODERMA.COM
45. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus
46. Under detection of interstitial lung disease in juvenile systemic sclerosis (jSSc)
47. Update from the juvenile scleroderma Inception Cohort
48. Is there a difference in presentation of female and male patients with juvenile systemic scleroderma?
49. Baseline structural damage predicts response to abatacept in patients with psoriatic arthritis: a post hoc analysis of the Phase III ASTRAEA Study
50. Baseline structural damage predicts response to abatacept in patients with psoriatic arthritis: a post hoc analysis of the Phase III ASTRAEA Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.